Trial Profile

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary)
Indications Early breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms POP-DURVA

Most Recent Events

08 Jul 2024 Planned number of patients changed from 195 to 200.
09 Dec 2023 Planned number of patients changed from 200 to 195, as per Trial design, presented at the 46th Annual San Antonio Breast Cancer Symposium
09 Dec 2023 Trial design, presented at the 46th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com